Literature DB >> 29549489

Perspectives on multidrug-resistant organisms at the end of life : A focus group study of staff members and institutional stakeholders.

Franziska A Herbst1,2, Maria Heckel3, Johanna M Tiedtke4, Thomas Adelhardt5, Alexander Sturm6,7, Stephanie Stiel8, Christoph Ostgathe3.   

Abstract

BACKGROUND: There is a lack of research into how hospital staff and institutional stakeholders (i. e. institutional representatives from public health authorities, hospital hygiene, and the departments of microbiology, palliative care, and geriatrics) engage with patients who are carriers of multidrug-resistant organisms and receiving end-of-life care. Knowledge of their experiences, workload, and needs should be considered in dealing with hospitalized carriers of multidrug-resistant organisms as well as staff education.
OBJECTIVE: This study explored and compared staff members' and stakeholders' perspectives on multidrug-resistant organisms and on provision of end-of-life care to carrier patients.
METHODS: In this study four focus groups consisting of hospital staff members and institutional stakeholders were formed within a mixed-methods parent study in a palliative care unit at a university clinic and a geriatric ward of a Catholic and academic teaching hospital. Participants discussed results from staff and stakeholder interviews from a former study phase. Data were analyzed according to Grounded Theory and perspectives of staff members and institutional stakeholders were compared and contrasted.
RESULTS: Key issues debated by staff members (N = 19) and institutional stakeholders (N = 10) were 1) the additional workload, 2) reasons for uncertainty about handling carrier patients, 3) the format of continuing education, and 4) the preferred management approach for dealing with multidrug-resistant organism carrier patients. Although similar barriers (e. g. colleagues' ambiguous opinions) were identified, both groups drew different conclusions concerning the management of these barriers. While institutional stakeholders recommended making decisions on hygiene measures under consideration of the specific patient situation, staff members preferred the use of standardized hygiene measures which should be applied uniformly to all patients. DISCUSSION: Staff members and institutional stakeholders perceived similar barriers to practice caused by multidrug-resistant organisms and similar needs for continuing education. The staff members' preferred management approach might originate from an uncertainty about the multidrug-resistant organism infection risk. Experiences and visions of both groups should be included in a specific recommendation for end-of-life care to ensure behavioral confidence.

Entities:  

Keywords:  Methicillin-resistant Staphylococcus aureus; Multidrug-resistant gram-negative bacteria; Multidrug-resistant organisms; Palliative care; Qualitative research

Mesh:

Year:  2018        PMID: 29549489     DOI: 10.1007/s00391-018-1378-8

Source DB:  PubMed          Journal:  Z Gerontol Geriatr        ISSN: 0948-6704            Impact factor:   1.281


  19 in total

Review 1.  The epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in Germany.

Authors:  Robin Köck; Alexander Mellmann; Frieder Schaumburg; Alexander W Friedrich; Frank Kipp; Karsten Becker
Journal:  Dtsch Arztebl Int       Date:  2011-11-04       Impact factor: 5.594

Review 2.  Isolation measures in the hospital management of methicillin resistant Staphylococcus aureus (MRSA): systematic review of the literature.

Authors:  B S Cooper; S P Stone; C C Kibbler; B D Cookson; J A Roberts; G F Medley; G Duckworth; R Lai; S Ebrahim
Journal:  BMJ       Date:  2004-09-04

3.  [Infection prevention in the home. Recommendations of the Commission for Hospital Hygiene and Infection Production of the Robert Koch Institute (RKI)].

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2005-09       Impact factor: 1.513

4.  A study of senior staff nurses' perceptions about MRSA.

Authors:  Laurence Lines
Journal:  Nurs Times       Date:  2006 Apr 11-17

5.  [Recommendations for prevention and control of methicillin-resistant staphylococcus aureus (MRSA) in medical and nursing facilities].

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2014-06       Impact factor: 1.513

6.  A survey of methicillin-resistant Staphylococcus aureus (MRSA) management in hospices/palliative care units.

Authors:  Pauline Dand; Joan Fyvie; Alethea Yee; Nigel Sykes
Journal:  Palliat Med       Date:  2005-04       Impact factor: 4.762

7.  Methicillin-resistant Staphylococcus aureus (MRSA) management in palliative care units and hospices in Germany: a nationwide survey on patient isolation policies and quality of life.

Authors:  Johannes Bükki; Jennifer Klein; Ludmilla But; Thomas Montag; Hans Martin Wenchel; Raymond Voltz; Christoph Ostgathe
Journal:  Palliat Med       Date:  2011-11-01       Impact factor: 4.762

8.  Infection control and management of MRSA: assessing the knowledge of staff in an acute hospital setting.

Authors:  P M Easton; A Sarma; F L R Williams; C A Marwick; G Phillips; D Nathwani
Journal:  J Hosp Infect       Date:  2007-02-20       Impact factor: 3.926

Review 9.  Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities.

Authors:  J E Coia; G J Duckworth; D I Edwards; M Farrington; C Fry; H Humphreys; C Mallaghan; D R Tucker
Journal:  J Hosp Infect       Date:  2006-04-03       Impact factor: 3.926

Review 10.  [Multiresistant gram-negative bacteria. A bacterial challenge of the twenty-first century].

Authors:  K Schröppel; R Riessen
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-03-13       Impact factor: 0.840

View more
  1 in total

1.  Addressing multidrug resistant pathogens in pediatric palliative care patients-the nurses point of view: A qualitative study.

Authors:  Pia Schmidt; Almut Hartenstein-Pinter; Julia Wager; Carola Hasan; Boris Zernikow
Journal:  Palliat Med       Date:  2019-10-29       Impact factor: 4.762

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.